52 results about "Posttraumatic stress disorders" patented technology

Provided are a device, system, and method for treating a patient having posttraumatic stress disorder (PTSD) or other such psychiatric disorder. An event being recounted by the patient is recorded and a sensory environment of the patient is controlled so as to administer exposure therapy to the patient. Patient mental state may be monitored during administration of the exposure therapy to the patient, and the exposure therapy may be varied in correspondence to the monitored mental state of the patient. In one embodiment, hierarchy assembly means creates a treatment hierarchy based on input from the patient, and hierarchy navigation means navigates within the treatment hierarchy in response to the mental state of the patient.

The invention provides a virtual reality therapy system for driving posttraumatic stress disorder. The virtual reality therapy system comprises a helmet display, a sound effect system, a driving console, a multichannel physiological monitoring device and a controller, wherein the helmet display is used for displaying a virtual scene, the sound effect system is used for outputting an audio signal matched with the virtual scene, the driving console is matched with the virtual scene, and the multichannel physiological monitoring device is used for monitoring physiological data of a user in real time. The virtual reality therapy system for the driving posttraumatic stress disorder is high in safety, remarkable in effect, high in controllability and short in therapy time.

A compound with general formula Ifor treatment of various diseases of the central nervous system, in treatment of neuropsychiatric disorders related to imbalance of glutamatergic neurotransmitter system, ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, PTSD and other diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addictions, multiple sclerosis, epilepsy and gliomas.

The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of GPR52. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a GPR52-mediated disorder (e.g., Huntington's disease, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder (ADHD), or Tourette's syndrome); an extrapyramidal or movement disorder; a motor disorder; a hyperkinetic movement disorder; a psychotic disorder; catatonia; a mood disorder; a depressive disorder; an anxiety disorder; obsessive-compulsive disorder (OCD); an autism spectrum disorder; a prolactin-related disorder (e.g., hyperprolactinemia); a neurocognitive disorder; a trauma- or stressor-related disorder (e.g., posttraumatic stress disorder (PTSD)); a disruptive, impulse-control, or conduct disorder; a sleep-wake disorder; a substance-related disorder; an addictive disorder; a behavioral disorder; hypofrontality; an abnormality in the tuberoinfundibular, mesolimbic, mesocortical, or nigrostriatal pathway; decreased activity in the striatum; cortical dysfunction; neurocognitive dysfunction; and conditions related thereto.

Described are reminiscence therapy and media sharing platform, methods, and systems for a patient user which provide an immediate and First Mobile Application positive impact on emotional functioning inpatients with dementia, major neurocognitive disorders, social isolation, traumatic brain injury (TBI), and psychiatric conditions such as posttraumatic stress disorder, by reducing anxiety, depression, and overall emotional distress.

The present invention provides novel compounds of formula I wherein W1, W2, W3, W4, W5, B, X1, X2, X3, X4, X5, E and L are as defined herein; invention compounds are gamma amino butyrique acid receptor-subtype B (“GABAB”) positive allosteric modulators (enhancers), which are useful to provide methods of treating or preventing diseases or disorders, including treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, panic disorder, posttraumatic stress disorders, urge urinary incontinence, gastroesophageal reflux disease, transient lower oesophageal sphincter relaxations, functional gastrointestinal disorders and irritable bowel syndrome.

The present invention relates to compounds of formulawhereinX is —S— or —NH—;R3 / R4 together with the N-atom to which they are attached form a non aromatic 5, 6 or 7 membered ring, which optionally contains in addition to the N-atom one additional heteroatom selected from the group consisting of O, S and N, and wherein the ring is optionally substituted by hydroxy, lower alkyl, lower alkoxy, —NR2, —CONR2, —CO-lower alkyl or benzyl; or R3 / R4 form together with the N-atom to which they are attached a heterocyclic ring system, containing two or three rings and which optionally contains one or two additional heteroatoms selected from the group consisting of N and O and which has no more than 20 carbon atoms; andR, R1, R2, and R5 are as defined herein and to pharmaceutically suitable acid addition salts thereof.It has been found that the compounds of the invention are active on the GABAB receptor and therefore are useful for the treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders and gastro-intestinal disorders.